Carboxylic acid-type lipid, and lipid particle and lipid membrane each comprising carboxylic acid-type lipid

Patent metadata

Field	Value
Publication number	US-12325677-B2
Application number	US-201917286448-A
Country	US
Kind code	B2
Filing date	Oct 17, 2019
Priority date	Oct 17, 2018
Publication date	Jun 10, 2025
Grant date	Jun 10, 2025

Abstract

A carboxylic acid-type lipid can accelerate adhesion or aggregation of platelets even if the carboxylic acid-type lipid does not carry a protein involved in adhesion or aggregation of platelets or a peptide corresponding to an active site of the protein; a lipid particle and a lipid membrane each include the carboxylic acid-type lipid; and a platelet aggregation accelerating agent, a platelet adhesion accelerating agent, a hemostatic agent and a platelet substitute each include the carboxylic acid-type lipid, the lipid particle or the lipid membrane. A carboxylic acid-type lipid is selected from carboxylic acid-type lipids represented by formulas (I) to (VI), a lipid particle includes the carboxylic acid-type lipid, a lipid membrane includes the carboxylic acid-type lipid, and a platelet aggregation accelerating agent, a platelet adhesion accelerating agent, a hemostatic agent and a platelet substitute each include the carboxylic acid-type lipid, the lipid particle or the lipid membrane.

First claim

The invention claimed is:

1. A compound having a structure represented by one of formulas (I) to (VI):

wherein, in formulas (I) to (VI),
M represents an amino acid residue, an amino acid derivative residue, a peptide residue or a salt thereof, wherein the amino acid residue, the amino acid derivative residue, the peptide residue and the salt thereof can be negatively charged at physiological pH,
the amino acid residue represented by M is an acidic amino acid residue or a neutral amino acid residue,
the amino acid derivative represented by M is a residue of a basic amino acid derivative, and an introduced derivatization that the basic amino acid derivative comprises is amidation of an amino group of a side chain of a basic amino acid to a group represented by a formula: —NH—CO—R1 wherein —NH— is derived from the amino group of the side chain of the basic amino acid, and R1 represents a hydrocarbon group,
the peptide residue represented by M is a peptide residue comprising one or more acidic amino acid residues,
R represents a hydrocarbon group,
L represents —CO—O—, —O—CO—, —CO—NH—, —NH—CO—, —CO—S—, —S—CO— or —S—S—,
X represents a hydrocarbon group, a neutral amino acid residue or a polyalkylene glycol residue,
p represents an integer of 0 or more,
q represents an integer of 0 or more,
Y represents a branched chain composed of a branched chain body and one or more groups Y2 that are bonded to the branched chain body, or represents a straight chain composed of one group Y2, wherein the branched chain body is composed of one or more units Y1, wherein each unit Y1 is represented by formula (VII):

and wherein each group Y2 is represented by formula (VIII):
(* b 4)-[L-X] p -L-R  (VIII)

wherein, in formulas (VII) and (VIII),
R, L, X, p and q are the same as defined above,
(*b1), (*b2) and (*b3) represent a bond of each unit Y1,
(*b4) represents a bond of each group Y2,
the bond (*b1) of each unit Y1 is bonded to (CH 2 ) q in formula (III), (IV) or (VI), or is bonded to a bond (*b2) or (*b3) of another unit Y1 constituting the branched chain body, and
the bond (*b4) of each group Y2 is bonded to (CH 2 ) q in formula (III), (IV) or (VI), or is bonded to a bond (*b2) or (*b3) of any unit Y1 constituting the branched chain body,
Z represents a branched chain composed of a branched chain body and one or more groups Z2 that are bonded to the branched chain body, or represents a straight chain composed of one group Z2, wherein the branched chain body is composed of one or more units Z1, wherein each unit Z1 is represented by formula (IX):

and wherein each group Z2 is selected from groups represented by formulas (X) and (XI):

wherein, in formulas (IX), (X) and (XI),
M, L, X, p and q are the same as defined above,
(*c1), (*c2) and (*c3) represent a bond of each unit Z1,
(*c4) and (*c5) represent a bond of each group Z2,
the bond (*c1) of each unit Z1 is bonded to (CH 2 ) q in formula (V) or (VI), or is bonded to a bond (*c2) or (*c3) of another unit Z1 constituting the branched chain body, and
the bond (*c4) or (*c5) of each group Z2 is bonded to (CH 2 ) q in formula (V) or (VI), or is bonded to a bond (*c2) or (*c3) of any unit Z1 constituting the branched chain body.

2. The compound according to claim 1 , wherein the acidic amino acid residue is an aspartic acid residue or a glutamic acid residue.

3. The compound according to claim 1 , wherein the peptide residue represented by M is a peptide residue comprising two or more acidic amino acid residues selected from an aspartic acid residue and a glutamic acid residue.

4. The compound according to claim 3 , wherein the peptide residue represented by M is a peptide residue represented by formula (XII):

wherein m is the same or different and represents 1 or 2.

5. The compound according to claim 1 , wherein L is the same or different and represents —CO—O—, —O—CO—, —CO—NH— or —NH—CO—.

6. The compound according to claim 1 , wherein Y is selected from straight and branched chains represented by formulas (XIII), (XIV), (XV) and (XVI):

wherein, in formulas (XIII) to (XVI),
Y1 represents one unit Y1,
Y2 represents one group Y2, and
(*b) represents a bond of the unit Y1 bonded to (CH 2 ) q in formula (III), (IV) or (VI).

7. The compound according to claim 1 , wherein Z is selected from straight and branched chains represented by formulas (XVII), (XVIII), (XIX) and (XX):

wherein, in formulas (XVII) to (XX),
Z1 represents one unit Z1,
Z2 represents one group Z2, and
(*c) represents a bond of the unit Z1 bonded to (CH 2 ) q in formula (V) or (VI).

8. A lipid, comprising the compound according to claim 1 and one or more lipids selected from a phospholipid, a glycolipid, a sterol and a fatty acid.

9. A method for affecting hemostasis, comprising administering the compound according to claim 1 to a bleeding site of a subject.

10. A composition, comprising the compound according to claim 1 and a pharmaceutically acceptable carrier or additive.

11. A method for affecting hemostasis, comprising administering the lipid according to claim 8 to a bleeding site of a subject.

12. A composition, comprising the lipid according to claim 8 and a pharmaceutically acceptable carrier or additive.

Assignees

• Toray Industries
• Nanotheta Co Ltd

Inventors

• Takeoka Shinji
• Nakahara Keiko
• NISHIURA Mamoru
• Otsubo Shinya
• Kurumatani Hajimu
• Arakane Toru

Classifications

• A61K47/64

  Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65) · CPC title

• A61K47/543

  Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine · CPC title

• A61K9/1271

  Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911}) · CPC title

• C07K5/06104

  with the first amino acid being acidic · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title